Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

Catamaran Bio Announces Lead CAR-NK Cell Therapy Programs and Upcoming Data Presentation at ASH 2021


Catamaran Bio, Inc., a biotechnology company developing off-the-shelf CAR-NK cell therapies to treat cancer, today announced that it has designated CAT-179, a HER2-targeted CAR-NK cell therapy, and CAT-248, a CD70-targeted CAR-NK cell therapy, as its first preclinical development programs. The company also announced that data supporting the CAT-248 program will be presented during a poster session at the 63rd Annual Meeting of the American Society of Hematology (ASH) which will be held virtually and in person in Atlanta from December 11-14, 2021.

At ASH, Catamaran will present data demonstrating the successful deployment of its proprietary TAILWINDtm platform to generate a CAR-NK cell therapy which demonstrates high levels of cytotoxicity against various tumor cell lines. Catamaran's TAILWINDtm platform provides an integrated CAR-NK solution that includes technology to overcome the immunosuppressive tumor microenvironment, CAR architectures optimized for NK cells, and non-viral transposon engineering for efficient manufacturing of CAR-NK cell therapies. The ASH presentation will focus on preclinical data supporting CAT?248, Catamaran's allogeneic CAR-NK cell therapy directed against CD70, a tumor antigen that is highly expressed on certain types of cancers, including renal cell carcinoma, pancreatic cancer, and acute myeloid leukemia. This work is a collaboration between Catamaran and the lab of Dr. Branden Moriarity, scientific co-founder of Catamaran and Associate Professor in the Department of Pediatrics, Division of Hematology/Oncology at the University of Minnesota Medical School.

"The unveiling of our initial two development programs demonstrates Catamaran's rapid progress toward delivering off-the-shelf CAR?NK cell therapies capable of reaching solid tumors," said Alvin Shih, MD, Chief Executive Officer of Catamaran Bio. "The new preclinical data we will be presenting at ASH demonstrate the viability and potential of our TAILWINDtm platform to enable a leading-edge solution for skillfully designing and efficiently manufacturing CAR-NK cell therapies for the treatment of cancer. We are excited to continue advancing our lead programs toward the clinic, as we seek to extend the transformative potential of cell therapy to patients with solid tumors."

The details of Catamaran's presentation at ASH 2021 are as follows:

About Catamaran Bio

Catamaran Bio is developing novel, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. We are using our TAILWINDtm platform, an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing NK cells and rapidly advance our pipeline of CAR-NK cell therapy programs. Our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell biology, engineering, manufacturing and clinical application. Catamaran is backed by leading financial and corporate investors, including SV Health Investors, Sofinnova Partners, Lightstone Ventures, Takeda Ventures, Astellas Venture Management, and the UMN Discovery Capital investment program. For more information, please visit www.catamaranbio.com and follow us on LinkedIn and @CatamaranBio on Twitter.


These press releases may also interest you

at 09:35
Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company, today announced it has completed a license with the University of California San Diego to add a novel gene therapy for the treatment of neurodegenerative diseases. Notably,...

at 09:35
The "Healthcare Consulting Services Market by Type of Service (Digital Health, IT, Operations, Strategy, Financial, HR & Talent), End User (Government Bodies, Healthcare Providers, Pharmaceutical & Biotechnology Companies), and Region - Global...

at 09:32
The Partnership for a Drug-Free New Jersey (PDFNJ) and the Office of the New Jersey Coordinator of Addiction Responses and Enforcement Strategies (NJ CARES), which is responsible for overseeing addiction-fighting efforts across the New Jersey Office...

at 09:30
India Globalization Capital, Inc. is excited to announce that the Board has appointed former Congressman Jim Moran ("Congressman Moran") as an independent Director. IGC is delighted to welcome Congressman Moran to its Board of Directors....

at 09:30
The "Global Single Cell Genomics Market Forecasts by End-user & Technology with Executive & Consultant Guides, Including Customized Forecasting and Analysis with COVID-19 Updates" report has been added to ResearchAndMarkets.com's offering. Single...

at 09:30
The Henry L. Hillman Foundation today announced the launch of the Healthy Aging Challenge, a public challenge that will award a total of $2 million to four winning proposals to improve the lives of older adults in southwestern Pennsylvania. This is...



News published on 4 november 2021 at 09:10 and distributed by: